To read the full story
Related Article
- FDA Approves Daiichi’s New ADC Datroway for Breast Cancer
January 21, 2025
- Daiichi’s TROP2 ADC Accepted for US FDA Review in Breast Cancer
April 3, 2024
- Daiichi Sankyo’s TROP2 ADC Now under Review for Breast Cancer in Japan
March 15, 2024
- EU Regulators Accept Daiichi Sankyo’s TROP2 ADC for Review in Lung, Breast Cancers
March 5, 2024
BUSINESS
- China Approves Eisai’s Insomnia Med Dayvigo
May 28, 2025
- Boehringer’s Japan Pharma Biz Grows 6 Years Running on Jardiance
May 28, 2025
- ALS Drug Radicava Now Available in Australia: Mitsubishi
May 28, 2025
- Renascience to Welcome Former MHLW Director as EVP
May 28, 2025
- Lilly/NCNP Tie Up for Research on APOE Gene Testing
May 27, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…